Retrospective multicenter study demonstrates early platelet improvement with eltrombopag in pediatric chronic immune thrombocytopenia, indicating benefits arise within six months.
Our study found that the benefits of eltrombopag treatment, in terms of platelet count improvement and use of additional therapies, are identifiable from the first 6 months of treatment.
No takes yet. Share an insight, caveat, or question.
Giordano et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: